OncoMatch/Clinical Trials/NCT06510491
Epcoritamab in Previously Treated WM
Is NCT06510491 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Epcoritamab for waldenstrom macroglobulinemia.
Treatment: Epcoritamab — This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+ (all degrees of positivity accepted))
CD20+ by immunophenotype or immunohistochemistry confirmed by bone marrow biopsy/aspirate (fresh or archival tissue acceptable) at time of most recent progression. All degrees of CD20 positivity will be accepted.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody (rituximab)
Prior therapies must have included an anti-CD20 antibody (e.g. rituximab)
Must have received: BTK inhibitor (ibrutinib, zanubrutinib)
Prior therapies must have included...a BTK inhibitor (e.g. ibrutinib, zanubrutinib)
Lab requirements
Blood counts
ANC ≥1000 cells/mcl (G-CSF allowed); ALC ≥200 cells/mcl; platelets ≥75,000 cells/mcl OR ≥50,000 cells/mcl with bone marrow involvement or splenomegaly (no PLT transfusions within 7 days); hemoglobin ≥8 g/dL (transfusion allowed)
Kidney function
creatinine ≤ institutional ULN OR creatinine clearance >45 ml/min
Liver function
total bilirubin ≤ 1.5x ULN (≤3x ULN if Gilbert's, direct bilirubin ≤2x ULN); AST(SGOT)/ALT(SGPT) ≤3× ULN
Participants must meet the following organ and marrow function as defined below: absolute neutrophil count ≥1000 cells/mcl (G-CSF allowed)...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- University of North Carolina at Chapel Hill · Chapel Hill, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify